Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancerAlessio Fiascarelli, Monica Binaschi|Breast Cancer Research and Treatment|2023Cited by 10
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D. Dubash, Shyamala Maheswaran, Brian Chirn et al.|Breast Cancer Research and Treatment|2023Cited by 6